| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Randomized Clinical Trial |
| Article Title |
Hydroxychloroquine-azithromycin, doubase C, and QTc prolongation in congolese patients with COVID-19: Myth or reality?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Brady Madioko Makanzu, Jean-Robert Makulo, Madone Ndona Mandina, Dimosi Roger Wumba, Murielle Mashi Longokolo, Hippolyte Situakibanza, Ossam Odio, Donat Sonzi Mangala, Constantin Mihigo Bashengezi, Benjamin Kabwe Mwilambwe, Gilbert Kabanda Kurhenga, Benjamin Longo-Mbenza and Roger Mwimba Mbungu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Brady Madioko Makanzu, MD, Doctor, Doctor, Department of Cardiology, Kinshasa University Hospital, Kinshasa, DR Congo , Kinshasa University Hospital, Kimwenza Road, Lemba Municipality, Kinshasa City, Kinshasa 11, Congo. bmaknzu@gmail.com |
| Key Words |
QTc prolongation; COVID-19; Doubase C; HCQ-AZT; Sub-Saharan Africa |
| Core Tip |
During the coronavirus disease 2019 (COVID-19) pandemic, western studies have shown the ineffectiveness and cardiotoxic effects of hydroxychloriquine and azithromycin (HCQ-AZI). In Africa, the heart toxicity of HCQ-AZI is little reported by cardiologists, and some african countries used these two molecules to treat COVID-19 patients. In the present study, we have evaluated the occurrence of prolongation of the QTc interval and torsade de pointes torsade in Congolese COVID-19 patients who received HCQ-AZI compared to Doubase C, a herbal medicine with broad-spectrum antiviral activity. |
| Publish Date |
2024-06-24 10:06 |
| Citation |
<p>Madioko Makanzu B, Makulo JR, Ndona Mandina M, Wumba DR, Mashi Longokolo M, Situakibanza H, Odio O, Sonzi Mangala D, Mihigo Bashengezi C, Kabwe Mwilambwe B, Kabanda Kurhenga G, Longo-Mbenza B, Mwimba Mbungu R. Hydroxychloroquine-azithromycin, doubase C, and QTc prolongation in congolese patients with COVID-19: Myth or reality? <i>World J Virol</i> 2024; 13(2): 90668</p> |
| URL |
https://www.wjgnet.com/2220-3249/full/v13/i2/90668.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v13.i2.90668 |
